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Abstract The mechanism of regulatory phosphorylation of the 
pyruvate dehydrogenase component (El) of muscle pyruvate 
dehydrogenase complex was studied. Chemical modification of 
the arginine residues essential for substrate binding was shown to 
prevent incorporation of 32p from [T-3zP]ATP into E1 catalyzed 
by kinase and to exclude completely the interaction of holo-E1 
with pyruvate. It is proposed that negatively charged phospho- 
seryl residues may compete with pyruvate for the active site 
arginine and thereby block the substrate binding. 
presence of [7-:~2p]ATP. Aliquots were removed and either assayed for 
PDC (El) activity or spotted on 2 × 2 cm Whatman 3MM paper and, 
following further treatment, counted for protein-bound radioactivity 
according to [11]. Protein was determined by the method of Bradford 
[12]. Arginine residues were modified with 2,3-butanedione, phenyl- 
glyoxal (PG) and 4-OH-3-NO2-PG as described earlier [13,14]. Un- 
reacted iketone reagents were removed by the gel-filtration techni- 
que. Kinase action in these experiments was controlled after 
combining native or modified El with saturating concentrations of
the E2-X-kinase fraction. Circular dichroism spectra were recorded 
on a CNRS-Russel-Jouan Dichrograph 1! 1 as described earlier [2]. 
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1. Introduction 
The activity of animal pyruvate dehydrogenase complex 
(PDC) is regulated by a phosphorylation-dephosphorylation 
cycle carried out by endogenous regulatory enzymes: kinase 
and phosphatase. The target of this covalent modification is 
pyruvate dehydrogenase (El) - the first component of PDC. 
E1 catalyzes the thiamine pyrophosphate (TPP)-dependent 
decarboxylation of pyruvic acid to produce 2-hydroxyethyl- 
TPP (HETPP), and reductive acetylation of lipoamide resi- 
dues attached to E2, the dihydrolipoamide acetyltransferase 
[1]. E1 exists as a tetramer (cq~)2, having two active sites [2]. 
Phosphorylation occurs at 3 seryl residues (Ser-264, Ser-271, 
Ser-203) located on the c~ subunit. It has been shown that 
phosphorylation of Ser-264 closely is correlated with major 
inactivation of the enzyme [3,4]. 
The mechanism of this effect is largely unknown. It was 
found that phosphorylation of pig heart E1 inhibited reac- 
tions leading to formation of HETPP [5]. Spectral studies 
used to monitor the separate steps of the enzyme action 
showed that pigeon breast muscle phospho-E1 was able to 
bind TPP in the active conformation to form a charge transfer 
complex, to convert HETPP in a half-of-the-site manner, but 
could not interact with the substrate pyruvate [6]. It was sug- 
gested that a negatively charged phosphoseryl residue may 
compete with pyruvate for the active site arginyl residue and 
thereby block the substrate binding. The aim of this work was 
to prove this hypothesis. 
2. Materials and methods 
PDC was isolated from pigeon breast muscle according to Jagan- 
nathan and Schweet [7], with some modifications. Resolution of PDC 
into components, namely El and E2 tightly binding protein X and 
kinase (E2-X-kinase), was carried out according to [8]. The PDC and 
El activities were measured as described previously [9,10]. Kinase was 
assayed by following enzyme inactivation and phosphorylation i  the 
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Fig. 1. Effect of puryvate on the time course of PDC inactivation 
(upper) and 32p incorporation (lower) under the action of endogen- 
ous E1 kinase. Concentrations: 1.46 mg/ml PDC and 0.5 mM 
[7-z2p]ATP, 80000 cprrdnmol (1); as (1) plus 2.5 mM (2) or 5 mM 
(3) puryvate. 
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Fig. 2. Effect of chemical modification of E1 arginine residues on its 
phosphorylation by kinase. Concentrations: El, 0.32 mg/ml; E2-X- 
kinase, 0.64 mg/ml, and ['/-32p]ATP, 0.5 mM, 80000 cpmJnmol. 
Curves 1,2, phosphorylation a d inactivation of the intact El, re- 
spectively; curves 3,4, 32p incorporation i to E1 modified by 2,3-bu- 
tanedione to residual activity of 35 and 4%, respectively; curve 5, 
phosphorylation f El modified at two arginine residues per mole 
with 4-OH-3-NO2-PG. 
3. Results and discussion 
Fig. 1 shows the correlation between the extent of phos- 
phorylation and PDC activity changing under the action of 
ATP-dependent kinase. The addition of pyruvate in increasing 
concentrations e sentially decreases the extent of enzyme in- 
activation and phosphorylation. Such substrate analogs as 
pyruvamide and acetylphosphinate also displayed protective 
effects in similar experiments (not shown). Thus, pyruvate 
and its analogs saturating E1 prevent enzyme inactivation 
and phosphorylation under the action of protein kinase. 
This suggests that protection can be achieved at the level of 
E1 active sites and be connected with the binding of ligands. 
A specific site on the protein essential for phosphorylation of
the regulatory center can be somewhat involved in the forma- 
tion of the holoenzyme-substrate (analog) complex. Such a 
site could be a arginine residue located in the E1 active center 
in the region of the holo-E1 interaction with pyruvate [13]. In 
this case any modification of the functionally important argi- 
nine residue should prevent not only substrate binding, but 
also phosphorylation of the serine residue performed by the 
protein kinase in the closely located regulatory site 
In order to confirm or disprove this hypothesis we studied 
the effect of chemical modification of the essential arginine 
residues on the ability of E1 to bind pyruvate or be a sub- 
strate for the ATP-dependent protein kinase. 
Fig. 2 (curve 1) shows that more than 2 moles of 32p are 
incorporated per E1 molecule during enzyme inactivation i  a 
control assay containing unmodified E1 in the system 
(El+E2-X-kinase). The extent of phosphorylation decreases 
up to 1 mol of 32p per mol of E1 after modification of the 
arginine residues by 2,3-butanedione up to 35% of the residual 
activity (curve 3). Practically no incorporation of 32p into the 
protein was detected after further E1 inactivation up to 4% of 
the residual activity (curve 4). It is possible that the first level 
of inactivation correlates with arginine residue modification i  
one of the two E1 active sites and blockage of the phospho- 
rylation reaction on one of the two a subunits of (~13)2 tetra- 
mer. The second level of inactivation can be associated with 
modification of the arginine residues in both active sites. This 
prevents alternating phosphorylation of serine residue on the 
second ~ subunit of the E1 tetramer. 
Previously, the number of essential E1 arginine residues was 
determined with the use of the chromophore reagent 4-OH-3- 
NO2-PG and found to be two per enzyme molecule [14]. Fig. 
2 (curve 5) shows that the enzyme modified by two arginine 
residues with 4-OH-3-NO2-PG is not able to be phosphoryl- 
ated. Hence E1 modified at the essential arginine residues 
completely loses the ability to serve as a substrate for the 
kinase. 
Furthermore, we studied the effect of modification of the 
arginine residues on the ability of E1 to bind pyruvate. For 
this purpose E1 was modified at two arginine residues, then 
TPP was added followed by pyruvate. The binding of the 
ligands was controlled by the quantitative registration of 
charge transfer complex band. Fig. 3 shows that the modified 
E 1 binds TPP with the same affinity as the native enzyme, but 
is not able to bind pyruvate. This is verified by the absence of 
any changes in the charge transfer complex band spectrum 
after the addition of pyruvate. 
Thus, we have shown that the ability of E1 to bind pyru- 
vate or its susceptibility o phosphorylation at the regulatory 
sites depends on the arginine residues being intact. Interaction 
of the functionally important arginine residues with chemical 
reagents or substrates prevents phosphorylation of serine res- 
idues in regulatory sites. This provides evidence for the close 
location of the substrate binding and regulatory sites. The 
binding of pyruvate by the guanidinium group of arginine 
in the active site probably neutralizes the local positive charge 
essential for orientation of the terminal ATP phosphate par- 
ticipating in the action of kinase. On the other hand, phos- 
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Fig. 3. Effect of chemical modification of E1 arginine residues on 
the intensity of the charge transfer complex band during enzyme 
saturation by TPP (a), and TPP+pyruvate (b). Concentration of E1 
was 1.9 mg/ml; (A) intact enzyme and (e) modified at two arginine 
residues per mole, respectively. 
98 
pho-Ser formation in the regulatory site prevents pyruvate 
binding in the E1 active site as shown previously [6]. 
The results obtained allow one to conclude that E1 inacti- 
vation upon phosphorylation may be due to competition be- 
tween the negatively charged phosphorine group and pyruvate 
carboxylic group for the positive charge of the arginine gua- 
nidinium group, located on the joint of the active and regu- 
latory sites. 
The interaction of the substrate binding sites and phospho- 
rylation sites has previously been suggested for isocitrate de- 
hydrogenase [15] and branched chain ct-ketoacid ehydrogen- 
ase [16]. Recently, the inactivation of the phosphorylation site 
mutants of human E1 has shown that phosphorylation of 
each of three sites leads to enzyme inactivation [17]. The 
mechanism we propose could explain the inactivation by 
phosphorylation of one of the three sites (probably Ser-264, 
site 1). Phosphorylation of sites 2 and 3 may affect the activity 
of E1 in different ways. 
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